PharmAthene to Present at the Leerink Swann 2012 Global Healthcare Conference on February 15, 2012

_{//health-fitness.news-articles.net/content/2012/ .. l-healthcare-conference-on-february-15-2012.html}
^{Published in Health and Fitness on Wednesday, February 8th 2012 at 7:50 GMT by Market Wire}  

PharmAthene to Present at the Leerink Swann 2012 Global Healthcare Conference on... -- ANNAPOLIS, Md., Feb. 8, 2012 /PRNewswire/ --

[ ]

My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about PIP

ANNAPOLIS, Md., Feb. 8, 2012 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: [ PIP ]), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that Eric I. Richman, President and Chief Executive Officer will present at the Leerink Swann 2012 Global Healthcare Conference on Wednesday, February 15, 2012 at 12:00 pm EST at the Waldorf Astoria Hotel, New York.

Mr. Richman will also be available to participate in one-on-one meetings at the conference.

Event:  Leerink Swann 2012 Global Healthcare Conference
Date:  Wednesday, February 15, 2012 at 12:00 pm
Place:  Waldorf Astoria Hotel, New York
Time:  12:00 pm EST

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

• SparVax™ - a second generation recombinant protective antigen (rPA) anthrax vaccine
• Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
• Recombinant BChE - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents

In addition, pursuant to an opinion issued September 22, 2011 from the Delaware Court of Chancery, PharmAthene is entitled to 50% of the profits over 10 years from all sales of SIGA Technologies' ST-246, and related products, a novel smallpox antiviral agent being developed by SIGA for the treatment and prevention of morbidity and mortality associated with exposure to the causative agent of smallpox (once SIGA receives the first $40 million in net profits from sales of ST-246.) For more information about PharmAthene, please visit [ www.PharmAthene.com ].

SOURCE PharmAthene, Inc.

RELATED LINKS
[ http://www.pharmathene.com ]